Repligen Corporation
RGEN
NGS
Sector: Healthcare
Industry: Biotechnology
246.49
USD
-9.72
(-3.79%)
Optionable: Yes Market Cap: 13,587 M 90-day average vol: 538,124
Previous close: 256.21 Open: 257.55 Bid: 314.0 Ask: 314.0
52 week range
137.21 327.32
Last updated: Friday 12th August 2022
Get Access to 1 Billion Usable Market data points IN YOUR EXCEL SHEETS WITH EASY TO USE EXCEL FUNCTIONS
Get started todaySearch for a stock
Are you?
Metrics
Valuation
Price per Sales TTM ($) | 17.45 |
Price per Book TTM ($) | 7.70 |
PE Ratio (TTM) | 90.40 |
Book Value per Share ($) | 31.87 |
5 Year PE Range49.5 |
Returns
7 Day Return | 1.31% | |
1 Month Return | 52.21% | |
3 Month Return | 63.89% | |
1 Year Return | -1.26% | |
3 Year Return | 173.63% | |
5 Year Return | 492.38% | |
YTD Return | -6.93% |
Risk
Custom Beta One Year | 1.35 |
Custom Beta Three Years | 0.93 |
Beneish M Score | -1.47 |
Altman Z Score | 11.92 |
Analyst Estimates
Financial Health
Technicals
RSI (14 Day) | 71.22 |
14 Day SMA ($) | 229.23 |
14 Day EMA ($) | 230.29 |
Money Flow Index | 80.03 |
Average True Range | 10.44 |
50 Day SMA ($) | 182.28 |
200 Day SMA ($) | 200.48 |
ADX | 51.02 |
MACD | 21.36 |
Growth
Free Cash Flow QoQ Growth | -131.48% |
Free Cash Flow YoY Growth | 0.00% |
Revenue YoY Growth | 0.00% |
EPS QoQ Growth | 60.38% |
Revenue QoQ Growth | 10.66% |
EPS YoY Growth | 0.00% |
Profitability
Chart
News
Agios (AGIO) Gets FDA Nod for Rare Anemia Drug Mitapivat
Yahoo Finance 2/18/2022
Repligen (RGEN) Q4 Earnings and Revenues Surpass Estimates
Yahoo Finance 2/18/2022
Repligen's Q4 Earnings Beat Expectations, Issues Solid FY22 Guidance
Yahoo Finance 2/17/2022
Repligen (RGEN) CEO, Tony Hunt on Q4 2021 Results - Earnings Call Transcript
Seeking Alpha 2/17/2022
Repligen (RGEN) Tops Q4 Earnings and Revenue Estimates
Yahoo Finance 2/17/2022
Repligen Non-GAAP EPS of $0.81 beats by $0.16, revenue of $186.52M beats by $8.25M
Seeking Alpha 2/17/2022
Repligen Reports Fourth Quarter and Full Year 2021 Financial Results
Yahoo Finance 2/17/2022
Repligen Q4 2021 Earnings Preview
Seeking Alpha 2/16/2022
Medical Stocks' Q4 Earnings on Feb 17: RGEN, IRWD & More
Yahoo Finance 2/16/2022
Repligen launches AAV affinity resins for gene therapy manufacturing workflows
Seeking Alpha 2/15/2022
Repligen Launches AAV Affinity Resins for Gene Therapy Purification
Yahoo Finance 2/15/2022
Repligen: Replicating Great Returns
Seeking Alpha 2/14/2022
Repligen Corporation to Present at 11th Annual SVB Leerink Healthcare Conference
Yahoo Finance 2/11/2022
Repligen (RGEN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Yahoo Finance 2/10/2022
Best Stocks to Buy Now for February 2022
Yahoo Finance 2/8/2022
Was The Smart Money Right About Repligen Corporation (RGEN)?
Yahoo Finance 2/6/2022
Repligen to Report Fourth Quarter and Full Year 2021 Financial Results
Yahoo Finance 2/3/2022
Trend Analysis & Forecast
Read more on this trend analysis & forecast here - uptrenddowntrend.com
Trendlast: 82.073
Financials
RGEN Income Statement
Annual
| Dec-12 | Dec-13 | Dec-14 | Dec-15 | Dec-16 | Dec-17 | Dec-18 | Dec-19 | Dec-20 | Dec-21 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 62 M | 68 M | 64 M | 84 M | 105 M | 141 M | 194 M | 270 M | 366 M | 671 M |
| Cost of sales | 24 M | 22 M | 24 M | 31 M | 42 M | 57 M | 71 M | 98 M | 130 M | 241 M |
| Gross operating profit | 35 M | 43 M | 36 M | 48 M | 57 M | 74 M | 108 M | 151 M | 210 M | 391 M |
| Selling Gen & administrative expense | 13 M | 13 M | 17 M | 25 M | 31 M | 52 M | 66 M | 96 M | 120 M | 184 M |
| Research & development expense | 10 M | 7 M | 6 M | 6 M | 7 M | 9 M | 16 M | 19 M | 20 M | 34 M |
| Operating income | 11 M | 23 M | 13 M | 18 M | 19 M | 14 M | 26 M | 36 M | 70 M | 173 M |
| floaterest income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| floaterest expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other income net | -51626 | 100000 | -2 M | -4 M | -4 M | -316000 | 2 M | -640000 | 2 M | -7 M |
| Pre-tax Income (EBT) | 11 M | 23 M | 11 M | 13 M | 12 M | 7 M | 21 M | 26 M | 59 M | 154 M |
| Income taxes | -3 M | 7 M | 3 M | 4 M | 11000 | -21 M | 5 M | 5 M | -709000 | 25 M |
| Net income from total operations | 14 M | 16 M | 8 M | 9 M | 12 M | 28 M | 17 M | 21 M | 60 M | 128 M |
| Minority floaterest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total net income | 14 M | 16 M | 8 M | 9 M | 12 M | 28 M | 17 M | 21 M | 60 M | 128 M |
| Preferred dividends | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net income available for common | 14 M | 16 M | 8 M | 9 M | 12 M | 28 M | 17 M | 21 M | 60 M | 128 M |
| Depreciation | 4 M | 3 M | 4 M | 5 M | 5 M | 11 M | 16 M | 21 M | 27 M | 38 M |
| Amortization | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating income before depreciation (EBITDA) | 15 M | 26 M | 15 M | 18 M | 21 M | 24 M | 44 M | 56 M | 98 M | 205 M |
| Total Income available for floaterest expense (EBIT) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Basic EPS total | 0.46 | 0.51 | 0.25 | 0.28 | 0.35 | 0.74 | 0.38 | 0.44 | 1.14 | 2.33 |
| Diluted EPS total | 0.45 | 0.5 | 0.25 | 0.28 | 0.34 | 0.72 | 0.37 | 0.44 | 1.11 | 2.24 |
Top MarketXLS Rank stocks
Call: 1-877-778-8358
I am so happy you are here. My name is Ankur and I am the founder/CEO of MarketXLS. Over the past four years, I have helped more than 2500 customers to implement their own investment research strategies and monitoring systems in Excel.
Get Access to 1 Billion Usable Market data points IN YOUR EXCEL SHEETS WITH EASY TO USE EXCEL FUNCTIONS
Get started today
Stand with Ukraine
As the situation in Ukraine escalates, many of us in MarketXLS are left with emotions too overwhelming to name. If you’d like to show your support, but aren’t sure how to, we want to help make it easier for you to act.
For any amount donated, we’ll extend your MarketXLS subscription for double of the donated amount. Please send proof of your payment to support@marketxls.com to avail the extention
From all of us at MarketXLS, thank you!